Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study

Dell’ova, M.; Maio, Eléonora De; Guiu, Séverine; Roca, Lise; Dalenc, Florence; Durigova, Anna; Pinguet, Frédèric; Bekhtari, K.; Jacot, William; Pouderoux, Stéphane

doi:10.1186/s12885-015-1673-3

Cited by 35 publications

(46 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, the ERIBEX trial, a retrospective, international, multicenter study involving 258 patients receiving eribulin for a locally advanced or metastatic breast cancer, HER2 positivity seemed to be a predictive factor, with a significant increase in clinical benefit rate in HER2 positive tumors compared to those HER2 negative (HR 0.38, p = 0.02). This could be probably due to the systematic use of trastuzumab in association with eribulin, in the population of ERIBEX study [24]. In our Cox proportional hazards model, there was no significant difference in PFS according to hormone receptor expression and HER2 positivity, even if HR values for hormone-positive disease were near or superior to 1, thus suggesting potentially worse PFS curves in these patients.…”

Section: Discussionmentioning

confidence: 72%

Predictive Factors of Eribulin Activity in Metastatic Breast Cancer Patients

et al. 2018

View full text Add to dashboard Cite

Objectives: Predictive factors of response to eribulin are lacking. We aimed to investigate the activity and safety of eribulin in a real-world population of metastatic breast cancer (MBC) patients and to identify possible predictive factors of progression-free survival (PFS) and objective response. Methods: We retrospectively analyzed 71 eribulin-treated MBC patients. Best response rate, PFS, and adverse events (AEs) were evaluated. The impact of different clinical-pathological factors on PFS was evaluated using the Cox proportional hazards model. Predictive factors of response were identified by discriminant function analysis (DFA). Results: Median PFS was 3.75 months (95% CI, 2.39–4.48); 12 patients (16.90%) achieved partial response (PR), 27 (38.03%) stable disease. The most common AEs were fatigue (25.83%), neutropenia (16.56%), and peripheral neuropathy (13.91%). A worse performance status (p = 0.025) and a higher number of metastatic organ sites (p = 0.011) were associated with a worse PFS under eribulin. Overall, in the DFA-predictive model, neutrophil-to-lymphocyte ratio at baseline, estrogen receptor, Ki67, histology, and age were predictive of PR with 100% accuracy. Conclusions: Activity and safety profiles of eribulin were consistent with literature data. Performance status and number of metastatic sites were predictive factors of PFS. DFA could be a promising tool to discriminate responses to eribulin among MBC patients.

show abstract

Section: Discussionmentioning

confidence: 72%

Predictive Factors of Eribulin Activity in Metastatic Breast Cancer Patients

et al. 2018

View full text Add to dashboard Cite

show abstract

“…[19][20][21] Gamucci et al 19 reported a favourable efficacy/safety ratio for eribulin in a multicentre observational Italian study involving 133 patients with MBC previously treated with at least two chemotherapy lines. Compared with our experience, the rates of overall response and stable disease were nearly identical (partial response 21.1% vs 17.5%, stable disease 42.8% vs 46.7%, respectively).…”

Section: Discussionmentioning

confidence: 99%

Eribulin for metastatic breast cancer (MBC) treatment: a retrospective, multicenter study based in Campania, south Italy (Eri-001 trial)

et al. 2017

View full text Add to dashboard Cite

BackgroundOn the basis of the results of two pivotal phase III clinical trials, eribulin mesylate is currently approved in EU for the treatment of advanced breast cancer (aBC) in patients who have previously received an anthracycline and a taxane in either the adjuvant or the metastatic setting, and at least one chemotherapeutic regimen for metastatic disease.MethodsIn our study, we investigated the efficacy and tolerability of eribulin as second or further line chemotherapy in 137 women affected by aBC.ResultsEribulin as monotherapy provided benefit in terms of progression-free survival (PFS), response rate (RR) and disease control rate (DCR) independently of its use as second or late-line therapy. The overall RR and DCR were 17.5% and 64%, respectively. In particular, DCR and overall RR were 50% and 13.6%, 65.4% and 21.1%, 70.4% and 14.8% and 66.7% and 16.7% in second, third, fourth and further lines of treatment, respectively. Median PFS (mPFS) according to the line of therapy was 5.7, 6.3, 4.5 and 4.0 months in patients treated with eribulin in second, third, fourth and over the fourth line, respectively. No significant difference in terms of mPFS was found between the various BC subtypes. Overall, eribulin resulted safe and most adverse events were of grade 1 or 2 and easily manageable. Grades 3–4 toxicities were neutropaenia and neurotoxicity.ConclusionsWith the limitations due to the observational nature of our findings, eribulin was shown to be an effective and safe therapeutic option in heavily pretreated patients with aBC.

show abstract

“…Additionally, several studies have demonstrated that eribulin is clinically-effective in patients with breast cancer (14,15). In a pooled analysis of patients with metastatic breast cancer who had received at least one prior chemotherapy regimen, eribulin significantly extended overall survival (OS), and increased the progression-free survival (PFS) and clinical benefit rates compared with the control treatments (15).…”

mentioning

confidence: 99%